ALMS vs BMY
ALMS: A clinical-stage biopharmaceutical company developing TYK2 inhibitors to replace broad immunosuppression with targeted therapies for immune-mediated diseases, with lead candidate envu advancing toward 2026 FDA submission. BMY: Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse modalities like biologics and CAR-T cell technology.
Side-by-side fundamentals
| Metric | ALMS | BMY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.81 | $60.76 | |
| Market cap as of 2026-07-23 | $3.8B | $124.9B | |
| P/E as of 2026-07-23 | n/a | 20.91 | |
| PEG as of 2026-07-23 | n/a | -4.29 | |
| Net margin as of 2026-07-23 | -1013.2% | +12.3% | BMY higher |
| Gross margin as of 2026-07-23 | n/a | +53.7% | |
| Operating margin as of 2026-07-23 | -1109.1% | +17.1% | BMY higher |
| ROE as of 2026-07-23 | -54.7% | +41.6% | BMY higher |
| ROA as of 2026-07-23 | -43.6% | +8.7% | BMY higher |
| Debt / equity as of 2026-07-23 | 0.00 | 2.22 | ALMS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +1.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +1.4% | |
| Dividend yield as of 2026-07-23 | n/a | +4.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.82 | 0.23 | |
| 1-year return as of 2026-07-22 close | +805.1% | +26.5% | ALMS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.